0001562180-22-007176.txt : 20221012
0001562180-22-007176.hdr.sgml : 20221012
20221012183129
ACCESSION NUMBER: 0001562180-22-007176
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221003
FILED AS OF DATE: 20221012
DATE AS OF CHANGE: 20221012
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Coric Vlad
CENTRAL INDEX KEY: 0001704317
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41477
FILM NUMBER: 221307669
MAIL ADDRESS:
STREET 1: C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP
STREET 2: 234 CHURCH STREET
CITY: NEW HAVEN
STATE: CT
ZIP: 06510
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Biohaven Ltd.
CENTRAL INDEX KEY: 0001935979
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: D8
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 215 CHURCH STREET
CITY: NEW HAVEN
STATE: CT
ZIP: 06510
BUSINESS PHONE: 203-404-0410
MAIL ADDRESS:
STREET 1: 215 CHURCH STREET
CITY: NEW HAVEN
STATE: CT
ZIP: 06510
FORMER COMPANY:
FORMER CONFORMED NAME: Biohaven Research Ltd.
DATE OF NAME CHANGE: 20220629
4/A
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4/A
2022-10-03
2022-10-05
false
0001935979
Biohaven Ltd.
BHVN
0001704317
Coric Vlad
C/O BIOHAVEN LTD.
215 CHURCH STREET
NEW HAVEN
CT
06510
true
true
false
false
Chief Executive Officer
Common Shares
2022-10-03
4
J
false
0.00
0.00
A
569309.00
D
Effective as of the pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd. ("RemainCo") to holders of its common shares pursuant to the Separation and Distribution Agreement, dated as of May 9, 2022, by and among RemainCo, the Issuer and Pfizer Inc. ("Pfizer"), each outstanding restricted share unit of RemainCo was adjusted so that such restricted share unit became a restricted share unit in respect of Common Shares (each, an "Issuer RSU") and a restricted share unit in respect of RemainCo common shares. (Cont'd in FN2)
(Cont'd from FN1) As a result, the Reporting Person acquired restricted share units in respect of Common Shares in an amount determined in accordance with the Separation Agreement. At the effective time of the merger of a wholly owned subsidiary of Pfizer ("Merger Sub") with and into RemainCo pursuant to the Agreement and Plan of Merger, dated as of May 9, 2022, by and among RemainCo, Pfizer and Merger Sub, the Issuer RSUs accelerated and vested in full and will subsequently be settled in Common Shares.
This amendment is being filed to correct the amount of shares beneficially owned reported in the Form 4 filed on October 5, 2022 (the "Original Form 4"). The Original Form 4 inadvertently incorrectly reported that 105,950 Issuer RSUs accelerated and vested in full and were subsequently settled in Common Shares; however, as reflected in this amendment, 52,975 Issuer RSUs accelerated and vested in full and were subsequently settled in Common Shares. There were no other changes made to the information in the Original Form 4.
/s/ George Clark, Attorney-in-Fact
2022-10-12